/ARQT

ARQT Stock - Arcutis Biotherapeutics, Inc.

Q: What is the analyst price target for ARQT?

Analyst price target information is not currently available for ARQT.

Q: What is ARQT's market cap?

Market capitalization information is not currently available for ARQT.

Healthcare|Biotechnology|NASDAQ

$26.05-2.73%

$0.73 (-2.73%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+22.8%upside

Target: $31.99

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ARQT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.72

52W High$31.77

52W Low$11.13

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$196.54M	$59.61M	$3.69M	N/A	N/A
Gross Profit	$177.41M	$54.62M	$2.93M	$-763,000	$-455,000
Gross Margin	90.3%	91.6%	79.5%	N/A	N/A
Operating Income	$-128,397,000	$-241,101,000	$-301,627,000	$-206,529,000	$-136,645,000
Net Income	$-140,039,000	$-262,140,000	$-311,458,000	$-206,356,000	$-135,678,000
Net Margin	-71.3%	-439.8%	-8449.8%	N/A	N/A
EPS	$-1.16	$-3.78	$-5.66	$-4.17	$-3.80

Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Visit Website

Earnings History & Surprises

ARQT

Beat Rate

74%

Last 19 quarters

Avg Surprise

+20.2%

EPS vs Estimate

Beats / Misses

14/5

Last 12 quarters

Latest EPS

$0.06

Q4 2025

EPS Surprise History

Q1 24

-10.8%

$-0.72vs$-0.65

Q2 24

+46.7%

$-0.32vs$-0.60

Q3 24

+12.5%

$-0.42vs$-0.48

Q4 24

+21.4%

$-0.33vs$-0.42

Q1 25

+67.9%

$-0.09vs$-0.28

Q2 25

+4.8%

$-0.20vs$-0.21

Q3 25

+27.8%

$-0.13vs$-0.18

Q4 25

+160.0%

$0.06vs$-0.10

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 24, 2026	$0.02	—	—	—
Q4 2025	Oct 28, 2025	$-0.10	$0.06	+160.0%	✓ BEAT
Q3 2025	Aug 6, 2025	$-0.18	$-0.13	+27.8%	✓ BEAT
Q2 2025	May 6, 2025	$-0.21	$-0.20	+4.8%	✓ BEAT
Q1 2025	Feb 25, 2025	$-0.28	$-0.09	+67.9%	✓ BEAT
Q4 2024	Nov 6, 2024	$-0.42	$-0.33	+21.4%	✓ BEAT
Q3 2024	Aug 14, 2024	$-0.48	$-0.42	+12.5%	✓ BEAT
Q2 2024	May 14, 2024	$-0.60	$-0.32	+46.7%	✓ BEAT
Q1 2024	Feb 27, 2024	$-0.65	$-0.72	-10.8%	✗ MISS
Q4 2023	Nov 3, 2023	$-0.90	$-0.73	+18.9%	✓ BEAT
Q3 2023	Aug 8, 2023	$-1.22	$-1.16	+4.9%	✓ BEAT
Q2 2023	May 9, 2023	$-1.30	$-1.31	-0.8%	✗ MISS
Q1 2023	Feb 28, 2023	$-1.37	$-1.18	+13.9%	✓ BEAT
Q4 2022	Nov 8, 2022	$-1.54	$-1.89	-22.7%	✗ MISS
Q3 2022	Aug 4, 2022	$-1.38	$-1.31	+5.1%	✓ BEAT
Q2 2022	May 5, 2022	$-1.42	$-1.27	+10.6%	✓ BEAT
Q1 2022	Feb 22, 2022	$-1.41	$-1.42	-0.7%	✗ MISS
Q4 2021	Nov 4, 2021	$-1.09	$-1.14	-4.6%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.91	$-0.84	+7.7%	✓ BEAT
Q2 2021	May 4, 2021	$-0.96	$-0.76	+20.8%	✓ BEAT

Frequently Asked Questions about ARQT

What is ARQT's current stock price?

Arcutis Biotherapeutics, Inc. (ARQT) is currently trading at $26.05 per share. The stock has moved -2.73% today.

What is the analyst price target for ARQT?

The average analyst price target for ARQT is $32.00, based on 1 analyst.

What sector is Arcutis Biotherapeutics, Inc. in?

Arcutis Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ARQT's market cap?

Arcutis Biotherapeutics, Inc. has a market capitalization of $3.19 billion, making it a mid-cap company.

Does ARQT pay dividends?

No, Arcutis Biotherapeutics, Inc. does not currently pay a dividend to shareholders.